120 related articles for article (PubMed ID: 18600523)
1. Fatal myelotoxicity after azathioprine treatment.
Slanar O; Chalupná P; Novotný A; Bortlík M; Krska Z; Lukás M
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):661-5. PubMed ID: 18600523
[TBL] [Abstract][Full Text] [Related]
2. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
3. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism.
Boonsrirat U; Angsuthum S; Vannaprasaht S; Kongpunvijit J; Hirankarn N; Tassaneeyakul W; Avihingsanon Y
Lupus; 2008 Feb; 17(2):132-4. PubMed ID: 18250137
[TBL] [Abstract][Full Text] [Related]
5. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
6. Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A/*3C).
Kurzawski M; Dziewanowski K; Ciechanowski K; Droździk M
Transpl Int; 2005 May; 18(5):623-5. PubMed ID: 15819814
[No Abstract] [Full Text] [Related]
7. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
8. Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
Yenson PR; Forrest D; Schmiegelow K; Dalal BI
Am J Hematol; 2008 Jan; 83(1):80-3. PubMed ID: 17696202
[TBL] [Abstract][Full Text] [Related]
9. Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients.
Derijks LJ; van Helden RB; Hommes DW; Stokkers PC
Gut; 2008 Jun; 57(6):872. PubMed ID: 18477684
[No Abstract] [Full Text] [Related]
10. Mistaken identity: misclassification of TPMT phenotype following blood transfusion.
Cheung ST; Allan RN
Eur J Gastroenterol Hepatol; 2003 Nov; 15(11):1245-7. PubMed ID: 14560161
[TBL] [Abstract][Full Text] [Related]
11. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case.
Tavadia SM; Mydlarski PR; Reis MD; Mittmann N; Pinkerton PH; Shear N; Sauder DN
J Am Acad Dermatol; 2000 Apr; 42(4):628-32. PubMed ID: 10727309
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age.
de Boer NK; van Bodegraven AA; de Graaf P; van der Hulst RW; Zoetekouw L; van Kuilenburg AB
Ther Drug Monit; 2008 Jun; 30(3):390-3. PubMed ID: 18520612
[TBL] [Abstract][Full Text] [Related]
13. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis.
Hibi T; Naganuma M; Kitahora T; Kinjyo F; Shimoyama T
J Gastroenterol; 2003; 38(8):740-6. PubMed ID: 14505127
[TBL] [Abstract][Full Text] [Related]
14. Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression.
Leung M; Piatkov I; Rochester C; Boyages SC; Leong RW
Intern Med J; 2009 Feb; 39(2):121-6. PubMed ID: 19356188
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
[TBL] [Abstract][Full Text] [Related]
16. Ulcerative colitis: prolonged remission following azathioprine-induced pancytopenia.
Burke DA; Dixon MF; Axon AT
J Clin Gastroenterol; 1989 Jun; 11(3):327-30. PubMed ID: 2754221
[TBL] [Abstract][Full Text] [Related]
17. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Banerjee S; Bishop WP
J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase.
Perri D; Cole DE; Friedman O; Piliotis E; Mintz S; Adhikari NK
Eur Respir J; 2007 Nov; 30(5):1014-7. PubMed ID: 17978158
[TBL] [Abstract][Full Text] [Related]
19. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls.
Corominas H; Domènech M; González D; Diaz C; Roca M; García-González MA; Peña S; Baiget M
Am J Gastroenterol; 2000 Sep; 95(9):2313-7. PubMed ID: 11007234
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
